Heron Therapeutics remains a 'Hold' due to middling growth prospects and a lack of clinical pipeline or clear strategic direction. Acute care products ZYNRELEF and APONVIE are the primary growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results